News
-
-
-
-
-
-
-
-
-
PRESS RELEASE
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database
Abivax reports positive ABTECT Maintenance Part 2 results for obefazimod in refractory UC patients, demonstrating meaningful clinical benefit and strengthening safety database -